Releases
13. November, 2025
Financial Report Q3-2025
The Company has advanced well with its planned activities Closing the clinical and regulatory...
Releases
31. October, 2025
CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children
Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product...
Releases
21. August, 2025
Financial Report Q2-2025
The Company has advanced well with its planned activities Positive and clinical meaningful top-line...
Releases
14. August, 2025
Marketing Authorisation Application (MAA) for CT001 has been submitted to the European Medicines Agency (EMA) for acute pain management in children
The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency...
Releases
27. June, 2025
Cessatech Q&A – June company presentation
Selected top 5 summarized questions from investors… Q&A Cessatech_June
Releases
19. June, 2025
Strengthening Executive Management with the promotion of Martin Juhl
On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of...
Releases
11. June, 2025
Completion of the directed issue of shares
As announced on 28 May 2025, the Board of directors in Cessatech exercised an...
Releases
28. May, 2025
Positive top-line results from its final CT001 Study 0202
On 28 May – Cessatech A/S (“Cessatech” or “the Company”) announces top-line results from...
Releases
15. May, 2025
Financial Report Q1-2025
The Company has advanced well with its planned activities Positive CT001 MDR assessment Finalization...
Releases
30. April, 2025
Recruitment has completed in the Paediatric Study 0202
30150 paediatric patients have been recruited in Study 0202 as planned Study 0202 is...
Releases
Releases
28. February, 2025
Annual Report 2024
Today, Friday 28. February, Cessatech has released the Annual Report for 20024. We have...
Want to see all releases?
To see all releases including those not listed here, go to our filings and reports.